InMode faces a material patent infringement lawsuit and ITC investigation targeting its Morpheus8 product line, which is a key revenue driver. While the company plans to defend vigorously, the risk of an import ban or significant damages creates overhang. Traders should monitor ITC institution decisions (expected within 30 days) and any preliminary claim construction rulings. A negative ITC finding could disrupt a major product line. The stock may face pressure until clarity emerges on the scope of the claims and the likelihood of an exclusion order.
Price Chart
Executive Summary
InMode Ltd. disclosed in a 6-K filing that Serendia LLC filed a patent infringement lawsuit against the Company and its subsidiary Invasix Inc. in the Central District of California, alleging infringement of three U.S. patents related to dermatological treatment devices (including Morpheus8 products). The complaint seeks an injunction and damages. InMode intends to vigorously defend, denying infringement and asserting patent invalidity. A parallel ITC complaint was also filed seeking to block imports of the accused products. Given the early stage and lack of loss accrual, the financial impact is uncertain but the litigation introduces material legal risk.
Key Facts
- Serendia LLC filed a patent infringement lawsuit against InMode Ltd. and its subsidiary Invasix Inc. in the Central District of California on June 25, 2026.
- The lawsuit alleges infringement of three U.S. patents by InMode's Morpheus8 dermatological treatment products and associated platforms/consoles.
- The complaint seeks unspecified damages and an injunction against importation and sale of the accused products.
- A parallel complaint was filed with the U.S. International Trade Commission (ITC) seeking a limited exclusion order and cease-and-desist order.
- InMode stated it has not yet estimated a potential loss and has not recorded a liability in its financial statements as of the filing date.
- The company intends to vigorously defend against the claims and deny the allegations.
Financial Impact
Unknown at this stage; potential for significant damages and/or import ban on key product line (Morpheus8).
Risk Factors
- Potential ITC exclusion order barring import of Morpheus8 products into the U.S.
- Significant litigation costs and management distraction
- Possible damages award if infringement is found
- Uncertainty around patent validity and claim scope
- Risk of negative impact on revenue from a key product line if injunction is granted
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-003341 |
| Document: 0001178913-26-003341-index-headers.html | 0001178913-26-003341 |
| Document: 0001178913-26-003341-index.html | 0001178913-26-003341 |
| Document: 0001178913-26-003341.txt | 0001178913-26-003341 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $14.16 | awaiting T+20 | — | $13.72 (−3.11%) |
Oct 21, 2026 6d ago | SC 13D/A | $14.03 | awaiting T+20 | — | $13.72 (−2.21%) |
Oct 13, 2026 14d ago | Press Release | $14.31 | awaiting T+20 | — | $13.72 (−4.09%) |
Sep 16, 2026 5w ago | 6-K | $14.58 $14.31 | ▲ +1.89% | ▲ +5.06% | $13.72 (+5.90%) |
Aug 5, 2026 11w ago | 6-K | $15.21 $14.95 | ▲ +1.71% | ▲ +1.11% | $13.72 (+9.80%) |
Aug 3, 2026 12w ago | 6-K | $15.35 $14.96 | ▼ −2.54% | ▼ −3.78% | $13.72 (−10.62%) |
Jul 20, 2026 14w ago | 6-K | $15.36 $14.99 | ▼ −2.41% | ▼ −4.97% | $13.72 (−10.68%) |
Jul 13, 2026 15w ago | 6-K | $15.15 $15.19 | ▼ −0.26% | ▲ +2.92% | $13.72 (+9.44%) |
Jul 10, 2026 15w ago | 6-K | $15.28 $15.31 | ▲ +0.20% | ▼ −2.23% | $13.72 (−10.21%) |
Jun 25, 2026 17w ago | 6-K | $14.63 $15.09 | ▼ −3.14% | ▼ −1.88% | $13.72 (+6.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers